Tirzepatide works by activating GIP and GLP-1 receptors, which are involved in glucose-dependent insulin secretion. When blood glucose levels increase, the medication supports the pancreas in releasing insulin. This helps the body regulate circulating glucose more effectively.
Improved blood glucose control and changes in body weight can also contribute to better insulin sensitivity. Excess body fat, particularly around the abdomen, is associated with insulin resistance. By supporting weight reduction in appropriate patients, tirzepatide may indirectly improve the body's response to insulin.
The medication influences insulin sensitivity through several interconnected metabolic processes:
Increased insulin secretion: Tirzepatide stimulates insulin release from pancreatic beta cells when blood glucose levels are elevated.
Reduced glucagon secretion: It decreases glucagon release when glucose levels are high, helping limit excessive glucose production by the liver.
Improved glucose regulation: Its combined hormonal effects support better blood glucose management.
Weight reduction: Reduced body weight can improve insulin sensitivity and metabolic health.
Slower gastric emptying: Tirzepatide delays stomach emptying, particularly during initial treatment, which can help reduce post-meal blood glucose increases.
These mechanisms work together to support glucose regulation. However, increased insulin secretion and improved insulin sensitivity are different processes. Tirzepatide influences both glucose-related hormonal responses and metabolic factors associated with insulin resistance.
Tirzepatide can influence several aspects of metabolic health beyond insulin secretion. Its effects include changes in blood glucose levels, appetite regulation, food intake, and body weight. These changes can contribute to improvements in metabolic function among individuals with type 2 diabetes.
The extent of improvement in insulin sensitivity can vary depending on individual health conditions, body composition, treatment response, and lifestyle factors.
Several factors are relevant when understanding its metabolic effects:
Body composition: Changes in abdominal fat and overall body weight can influence insulin resistance.
Physical activity: Regular physical activity supports glucose utilization by muscles and can improve insulin sensitivity.
Dietary habits: Balanced meals containing fiber, protein, and appropriate carbohydrate portions support blood glucose management.
Treatment duration: Metabolic changes may develop over time, depending on individual responses to treatment.
Existing health conditions: Other metabolic conditions can influence glucose regulation and treatment outcomes.
Tirzepatide is administered as a once-weekly injection. Common side effects include nausea, diarrhea, vomiting, constipation, and decreased appetite. More serious risks can include pancreatitis, gallbladder problems, dehydration-related kidney problems, and hypoglycemia, particularly when combined with insulin or sulfonylureas.
Its use requires medical supervision, including consideration of existing health conditions, other medications, and individual treatment requirements.